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LETTERS TO THE EDITOR
Common Mutations in Arg304 of the p63 Gene in
Ectrodactyly, Ectodermal Dysplasia, Clefting Syndrome:
Lack of Genotype^Phenotype Correlation and
Implications for Mutation Detection Strategies
To the Editor:
Ectrodactyly, ectodermal dysplasia, and clefting (EEC) syndrome
(OMIM 129900) is an autosomal dominant developmental disor-
der, most cases of which are due to mutations in the gene en-
coding the transcription factor, p63 (Yang et al, 1998; Celli
et al, 1999). Mutations in p63 can also cause other ectodermal
dysplasia syndromes, including split hand^split foot malformation,
limb^mammary syndrome, and ankyloblepharon^ectodermal
dysplasia^clefting syndrome, although genetic heterogeneity is
known to occur in some cases (McGrath et al, 2001; van Bokhoven
et al, 2001). Nevertheless, in the EEC syndrome, the vast majority
of mutations comprise heterozygous mis-sense mutations in the
DNA-binding domain of p63 (van Bokhoven et al, 2001). By
contrast, p63 gene mutations in the other ectodermal dysplasia
syndromes usually a¡ect di¡erent parts of the protein. For exam-
ple, ankyloblepharon^ectodermal dysplasia^clefting syndrome is
typically associated with mutations in the p63 SAM domain
(McGrath et al, 2001). In the few EEC syndrome mutation reports
published thus far, a number of recurrent molecular abnormalities
in p63 have been identi¢ed, predominantly involving mutations in
5-methylcytosine in certain CpG sites (for a recent summary see
van Bokhoven et al, 2001). Interestingly, the sites of these frequent
p63 amino acid substitutions in EEC syndrome usually corre-
spond to the very same residues in the p53 protein that are
mutated in human cancers (Hernandez-Boussard et al, 1999).
We have searched for p63 gene mutations in six individuals
thought to have EEC syndrome and our results add to the data-
base of common mutations in that all patients had de novo mis-
sense mutations in Arg304, providing new evidence that this is
the most frequently mutated amino acid in this disorder.
To identify mutations in p63, following informed consent,
DNA was extracted from peripheral blood samples taken from
the a¡ected individuals and clinically normal parents (where pos-
sible) using a standard cold water lysis method. Individual exons
of the p63 gene were ampli¢ed by polymerase chain reaction
(PCR) and sequenced (van Bokhoven et al, 2001). Speci¢cally, to
amplify exon 8 and £anking introns of p63 the following primers
were used: forward primer 50 -TGGCTAAGCTGGTAGTACGT-30,
reverse primer 50 -CACAGGTCTTATCATGCAGC-30. The ex-
pected PCR product size was 352 bp. For PCR ampli¢cation, 250
ng genomic DNA was used as the template in an ampli¢cation
bu¡er containing 6.25 pmol of the primers, 37.5 nmol MgCl2,
5mmol of each nucleotide triphosphate, and 1.25 U Taq poly-
merase (Applied Biosystems,Warrington, U.K.) in a total volume
of 25 ml in an OmniGene thermal cycler (Hybaid, Basingstoke,
U.K.). The ampli¢cation conditions were 941C for 5min, followed
by 38 cycles of 941C for 45 s, 551C for 45 s, 721C for 45 s. Aliquots
(5 ml) of the PCR products were analyzed by 2% agarose gel
electrophoresis. PCR products were then sequenced directly
using Big Dye labeling in an ABI 310 genetic analyzer (Applied
Biosystems).
The cardinal clinical features in EEC syndrome are ectodermal
dysplasia, ectrodactyly, cleft lip/palate, and nasolacrimal defects
with renal anomalies, choanal atresia, and conductive deafness re-
presenting secondary features (Buss et al, 1995; Roelfsema and
Cobben, 1996). The clinical details of the individuals studied were
as follows.
Patient 1was a 31y old female with a right cleft lip and palate,
fused second and third digits of the right hand with a rudimen-
tary middle ¢nger, left hand syndactyly, ectodermal dysplasia,
and nasolacrimal duct anomalies. The ectodermal dysplasia pro-
duced nail, skin, dental, and hair defects including oligodontia
with enamel hypoplasia, patchy alopecia, and dystrophic nails.
No other family members were a¡ected. Her EEC syndrome
score, using established scoring criteria (Roelfsema and Cobben,
1996) was 12/18.
Patient 2 was a 35 y old female, with a cleft palate (but no cleft
lip), syndactyly of the right middle and ring ¢ngers, left ectro-
dactyly, ectodermal dysplasia, and nasolacrimal drainage defects.
Conductive hearing loss was present, giving an EEC score of
11/18. This individual had an a¡ected son who was not included
in this study.
Patient 3 was a 4 y old boy, who had four limb ectrodactyly,
cleft lip and palate, ectodermal dysplasia, and nasolacrimal de-
fects. There was no index ¢nger on the right hand with fusion
of shortened middle and ring ¢ngers, and in the left hand the
middle ¢nger was absent with fusion of the thumb and index
¢nger. Both feet had cleft deformities with short fourth and ¢fth
toes. The ectodermal dysplasia produced dry skin, patchy alope-
cia, and dystrophic nails. Mild conductive hearing loss was also
present. The EEC syndrome score was 16/18.
Patient 4 was a 4 wk old girl with no cleft lip or palate but
signs of choanal atresia, ectrodactyly of the right foot, a broad
right thumb with bi¢d tip, £exion contracture of the right index
¢nger, syndactyly of the right middle and ring ¢ngers, and nail
hypoplasia. There was no family history of ectodermal anomalies.
EEC syndrome score (to date, but lacking formal evaluation of
eyes and hearing) was 7þ/18.
Patient 5 was a 22 wk gestation fetus, terminated following
oligohydramnios and severe urogenital abnormalities detected
on mid-trimester ultrasound. Autopsy ¢ndings revealed split-
hand/split-foot anomalies a¡ecting both hands and feet with
missing second and third toes bilaterally. There were also signs
of multicystic renal dysplasia. There was no family history of
any inherited ectodermal or developmental disorders. EEC syn-
drome score, even allowing for lack of full-term development,
was 6þ /18.
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Patient 6 was a 34 y old female with four limb ectrodactyly,
bilateral cleft lip and palate, lacrimal duct defects, conductive
hearing loss, and urogenital tract anomalies. She also had
evidence of mental retardation. The EEC syndrome score was 17/
18. She also had a 10 y old daughter with EEC syndrome. The
phenotype in the daughter, however, was much less severe with
no evidence of any clefting and an overall EEC syndrome score
of 7/18.
Direct sequencing of DNA from these a¡ected individuals re-
vealed one of two point mutations in each case. In patients 1, 2, 3,
5, and 6 (and daughter) there was a heterozygous G-A substitu-
tion at nucleotide 911 within exon 8 of the p63 gene (based on
nucleotide numbering of the p63a isotype with the A of the start
codon as nucleotide 1). This converts an arginine residue (CGG)
to glutamine (CAG) and is designated R304Q. In patient 4 there
was a heterozygous C-Tsubstitution at nucleotide 910 that con-
verts the same arginine residue (CGG) to tryptophan (TGG) and
is designated R304W. Both mutations result in the loss of a re-
striction site for the endonucleases HpaII or MspI (C/CGG), and
this was used to verify the mutations and to establish that neither
was present in ampli¢ed DNA from either parent or in 100 con-
trol chromosomes. Speci¢cally, in ampli¢ed control DNA the
352 bp PCR product was completely digested into fragments
199 bp and 153 bp in size, but in the presence of either heterozy-
gous mutation, R304Q or R304W, one allele remained undi-
gested (Fig 1). No other potentially pathogenic p63 sequence
variations were identi¢ed.
Mutations in Arg304 have been reported in eight other fa-
milies with the EEC syndrome. Along with our data, the litera-
ture now contains 10 families with R304Q (Celli et al, 1999; van
Bokhoven et al, 2001) and four families with R304W (Wessagowit
et al, 2000; van Bokhoven et al, 2001) establishing this amino acid
as the most common site for p63 mutations in EEC syndrome.
Full clinical details have been published for 12 of these cases
and, in each, the mutation has occurred de novo. This particular
arginine residue has been shown to bind to DNA with direct
contact to a backbone phosphate. Amino acid substitutions of
Arg304 result in loss of this contact and can also impose steric
hindrance on DNA binding (Celli et al, 1999), thus impeding ac-
tivity of all isoforms of p63.
The heterogeneity of the clinical features in our patients with
EEC syndrome is also noteworthy given the presence of the same
mutated amino acid. It is evident that Arg304 mutations do not
give rise to a common phenotype. Instead, it is clear that other
factors, including the possible in£uence of other modifying
genes, combine to determine the ¢nal developmental abnormal-
ities. Similar observations have been made for other amino acid
substitutions in p63. For example, mutations in Arg280 may give
rise to either EEC syndrome or split hand^split foot malforma-
tion, or rarely, no detectable abnormalities (van Bokhoven et al,
2001). Collectively, these ¢ndings have important implications
for genetic counseling and for the implementation of DNA-
based prenatal testing in families at risk for recurrence of these
disorders (South et al, 2002).
Our data are also relevant to the design of strategies to detect
mutations in the p63 gene in EEC syndrome. We now recom-
mend initial PCR ampli¢cation of exon 8 and restriction endo-
nuclease digestion with HpaII (orMspI). This will rapidly disclose
the presence of either R304Q or R304W that together account
forE 25% of all pathogenetic p63 mutations in EEC syndrome.
If no mutation is detected, analysis of the other highly mutable
arginine residues in p63 (Arg204, 227, 279, and 280) should then
be pursued before examining other parts of the gene.
DNA and clinical information from patient 5 were kindly supplied byWhitney Neu-
feld-Kaiser, Eastside Maternal^Fetal Medicine Unit, Bellevue,WA.This work was
supported by a project grant from the National Foundation for Ectodermal Dysplasias
(NFED) and by Action Research. Additional funding for related studies on EEC
syndrome from the British Medical Association and the Research and Development
fund of the Royal Liverpool and Broadgreen University Hospitals is gratefully
acknowledged.
Takahiro Hamada, Ien Chan, Colin E.Willoughby,n
David R. Goudie,w John A. McGrath
Department of Cell and Molecular Pathology,
St John’s Institute of Dermatology,
The Guy’s, King’s College and St Thomas’ Hospitals’ Medical School,
St Thomas’ Hospital, London, U.K.;
nExperimental Ophthalmology Unit, Department of Medicine,
University of Liverpool, Liverpool, U.K.; wClinical Genetics,
Human Genetics Unit, Ninewells Hospital and Medical School,
Dundee, U.K.
REFERENCES
Buss PW, Hughes HE, Clarke A: Twenty-four cases of the EEC syndrome: clinical
presentation and management. J Med Genet 32:716^723, 1995
Celli J, Duijf P, Hamel BCJ, et al: Heterozygous germline mutations in the p53
homolog p63 are the cause of EEC syndrome. Cell 99:143^153, 1999
Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut PIARC: p53
mutation database. a relational database to compile and analyze p53 mutations
in human tumors and cell lines. Hum Mutat 14:1^8, 1999
McGrath JA, Duijf P, Doetsch V, et al: Hay^Wells syndrome is caused by mis-sense
mutations in the SAM domain of p63. Hum Mol Genet 10:221^229, 2001
Roelfsema NM, Cobben JM:The EEC syndrome: a literature study. Clin Dysmorphol
5:115^127, 1996
South AP, Ashton GH,Willoughby C, et al: EEC syndrome. heterozygous mutation
in the p63 gene (R279H) and DNA-based prenatal diagnosis. Br J Dermatol
146:216^220, 2002
van Bokhoven H, Hamel BC, Bamshad M, et al: p63 gene mutations in EEC syn-
drome, limb^mammary syndrome, and isolated split hand-split foot malfor-
mation suggest a genotype-phenotype correlation. Am J Hum Genet 69:
481^492, 2001
Wessagowit V, Mellerio JE, Pembroke AC, McGrath JA: Heterozygous germline
mis-sense mutation in the p63 gene underlying EEC syndrome. Clin Exp Der-
matol 5:441^443, 2000
Yang A, Kaghad M,WangY, et al: p63, a p53 homolog at 3q27^29, encodes multiple
products with transactivating, death-inducing, and dominant-negative activ-
ities. Mol Cell 2:305^316, 1998
Figure1. Restriction endonuclease digestion of PCR products spanning
exon 8 of p63 using HpaII shows that the heterozygous presence of the
mutations R304Q and R304W results in loss of a solitary HpaII cutsite
on one allele. In control DNA (cont), the PCR product is completely di-
gested into fragments 199- and 153-bp in size. By contrast there is an addi-
tional undigested band of 352-bp in ampli¢ed mutant DNA. (MW=0X174
HaeII molecular weight marker).
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